Navamedic launches Eroxon[®] in Finland

06 Nov 2024 09:10 CET

Oslo, 6 November 2024 - Building on the successful product launch of Eroxon[®]
in Norway and Sweden earlier this year, Navamedic ASA (OSE: NAVA), a Nordic
pharma company and reliable provider of high-quality products to hospitals and
pharmacies, is now launching Eroxon[®] across pharmacies in Finland. Eroxon[®]
will be the first clinically proven over-the-counter topical treatment for the
treatment of erectile dysfunction in men in Finland.

Eroxon[®] is part of Navamedic's increasingly growing Consumer Health category.
Since the product launched in Norway in February 2024, Eroxon[®] has already
become one of the top performing products within this category, and it is
expected to continue driving further growth. The product launch in Finland marks
the third launch this year and will be followed by a launch in Denmark in 2025.

The Finnish market for erectile dysfunction has significant potential. A recent
study[ [1]] concluded that 37 per cent of Finnish men above 18 years of age,
more than 800,000 men, have had first-hand experience with erectile dysfunction.
Two in three of these men had previously sought help to medically treat the
condition, indicating that men in Finland have a higher willingness to treat the
condition than their neighbours in other Nordic countries.

"Eroxon[®] is a fast-acting, safe, and easily accessible product designed to
help men enhance their sexual health and overall quality of life. With a
significant number of men in Finland experiencing erectile dysfunction and
showing interest in effective treatment options, we see strong market potential
for Eroxon[®] in supporting their health and well-being," said Jack Spira,
Medical Director at Navamedic.

Eroxon[®] offers a range of features which differentiates it from other forms of
treatments for erectile dysfunction. It is an effective and fast-acting gel
which typically helps men get an erection within ten minutes of application. It
has a good safety profile due to its local effect with no systemic absorption.
Eroxon[®] is approved as a treatment for erectile dysfunction in the EU and the
US.

[1] About the study

A total of 1,576 Finns aged 18 and over responded to the Eroxon® survey, which
was conducted in September-October 2024 (25/9-1/10/2024). The results are
weighted to be representative of the population. The number of respondents
varies by question. The survey was conducted by Taloustutkimus Oy. The maximum
margin of error for the entire respondent population is +/- 2.7 percentage
points.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic
Mobile: +47 951 78 680

About Navamedic

Navamedic ASA is a Nordic pharmaceutical company dedicated to enhancing people's
quality of life by being a reliable supplier of high-quality prescription,
consumer health, and hospital products to hospitals and pharmacies. Our growing
product portfolio has been carefully selected to meet current public health
concerns, such as obesity, Parkinson's disease, and gastro-related ailments, to
empower people to live healthier and more fulfilling lives.

What sets us apart is our deep-rooted commitment to understanding the needs and
requirements of the countries where we are present. Our local insight and
competence enable us to understand the specific needs of each country where we
operate and ultimately to gain market access. This makes us a preferred partner
for international companies expanding their footprint across the Nordics and
Benelux regions, through either in-licensing or out-licensing. Navamedic has
been listed on the Oslo Stock Exchange since 2006 (ticker: NAVA) and is
headquartered in Oslo, Norway.

For more information, please visit Navamedic.com.

More information:
Access the news on Oslo Bors NewsWeb site